Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3121-3140 of 3,900 trials

B-Cell Malignancies: MB-CART2219.1 Therapy

We are testing a new CAR T-cell therapy for adults and children with relapsed or refractory B-cell cancers. The study aims to find the right dose and evaluate its safety and effectiveness.

Relapsed/Refractory Lymphoma or ALL>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Ovarian Cancer: Olaparib Maintenance Therapy

We are studying the effects of Olaparib as a maintenance treatment for patients with newly diagnosed advanced ovarian cancer. This trial aims to understand its safety and how it may improve patient outcomes.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Ovarian Cancer: Olaparib Treatment Study

We are investigating the effects of Olaparib in patients with recurrent ovarian cancer who do not have BRCA mutations. The goal is to see if it helps maintain treatment benefits after initial therapy and to understand its safety and effectiveness.

Recurrent Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Recurrent Ovarian Cancer: Olaparib vs. Chemotherapy

We are studying whether olaparib can help patients with recurrent ovarian cancer live longer without disease progression after surgery, compared to standard chemotherapy. The trial also looks at safety and quality of life.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Patent Ductus Arteriosus: Paracetamol Treatment in Premature Infants

We are studying whether early treatment with Paracetamol helps extremely low birth weight infants with Patent Ductus Arteriosus avoid serious complications. This trial compares the effects of Paracetamol to a placebo.

Patent Ductus Arteriosus≤3 monthsConfirmation phase (III)Investigational MedicinesCardiologyPediatrics

Tardive Dyskinesia: Testing ADE513

We are studying a new medication to see if it helps reduce involuntary movements in people with moderate to severe tardive dyskinesia. The trial also looks at the safety and tolerability of this treatment.

Tardive Dyskinesia3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyPsychiatry

B-Cell Malignancies: EXS73565 Treatment Study

We are testing a new medication for individuals with relapsed or refractory B-cell malignancies. This study aims to find the best dose to ensure safety and effectiveness.

B-cell MalignanciesSafety phase (I)HematologyOncology

Advanced Solid Tumors: MK-8294 Treatment

We are evaluating a new treatment called MK-8294 for people with advanced solid tumors. The study aims to understand its safety and how well it works.

Breast CancerCervical Squamous Cell CarcinomaEndometrial Carcinoma1-2 yearsSafety phase (I)Oncology

Transfer Factor TFI for Recurrent Infections

We are testing a new treatment for people with frequent respiratory or urinary tract infections and recurrent herpes. The study aims to see if it can help reduce the number of new infections.

Recurrent Respiratory Tract InfectionsRecurrent Urinary Tract Infections6-12 monthsConfirmation phase (III)Infectious DiseasesPulmonologyUrology

Rheumatoid Arthritis: Spironolactone Study

We are investigating whether spironolactone can help reduce symptoms in people with active rheumatoid arthritis. The study will also monitor safety and other health indicators.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

Parkinson's Disease: Investigational Drug ARV-102

We are studying the safety and effects of ARV-102 in patients with Parkinson's disease. This research aims to understand how well the drug is absorbed and its potential benefits.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Allergic Rhinitis: Beltavac® Immunotherapy

We are studying the effectiveness and safety of Beltavac®, a new immunotherapy, for people with allergic rhinitis caused by house dust mites. The trial will also look at how it affects allergy symptoms and overall quality of life.

House Dust Mite Allergy>2 yearsConfirmation phase (III)Investigational MedicinesAllergologyOphthalmologyOtolaryngology

Corticobasal Syndrome: Glycerol Phenylbutyrate Study

We are investigating whether glycerol phenylbutyrate can lower nerve damage markers in patients with corticobasal syndrome. This study will also look at the safety and tolerability of the treatment.

Corticobasal Syndrome6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineNeurology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Diffuse Large B-Cell Lymphoma: Polatuzumab Vedotin with R-CHP

We are studying whether a new treatment combining polatuzumab vedotin with standard chemotherapy helps patients with diffuse large B-cell lymphoma live longer without disease progression compared to the current standard treatment.

Diffuse Large B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Malaria Treatment: INE963 Study

We are investigating a new compound, INE963, to see how safe it is and how well it works for treating malaria. This study will help us understand how the body handles this new treatment.

Malaria6-12 monthsSafety phase (I)Infectious DiseasesInternal Medicine

Solid Tumors: Valemetostat Tosylate with DXd ADCs

We are studying a new combination treatment for patients with solid tumors to evaluate its safety and effectiveness. This trial aims to find better options for managing cancer.

Solid TumorSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

SAPHO Syndrome: Etanercept Treatment Study

We are testing the safety and effectiveness of etanercept in patients with SAPHO syndrome who are already on standard treatments. This study aims to explore new treatment options for better management of their condition.

SAPHO Syndrome6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInfectious DiseasesRheumatology

BI 3031185: Tolerance Study in Healthy Men

We are testing how well different doses of a new medication are tolerated by healthy men. This study aims to gather important safety information for future use.

Healthy VolunteersSafety phase (I)

Neovascular Age-Related Macular Degeneration: Port Delivery System with Ranibizumab

We are studying a new delivery system for ranibizumab in patients with neovascular age-related macular degeneration. The goal is to see how well it works and how it affects patients' treatment experiences.

Neovascular Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology